ATE255091T1 - 1-acetyl-5-bromo-4,6-dimethylindolin - Google Patents

1-acetyl-5-bromo-4,6-dimethylindolin

Info

Publication number
ATE255091T1
ATE255091T1 AT01114083T AT01114083T ATE255091T1 AT E255091 T1 ATE255091 T1 AT E255091T1 AT 01114083 T AT01114083 T AT 01114083T AT 01114083 T AT01114083 T AT 01114083T AT E255091 T1 ATE255091 T1 AT E255091T1
Authority
AT
Austria
Prior art keywords
inhibitors
pharmaceutically acceptable
acat
hyperlipemia
useful
Prior art date
Application number
AT01114083T
Other languages
English (en)
Inventor
Hiroshi Matsui
Shoji Kamiya
Hiroaki Shirahase
Shohei Nakamura
Katsuo Wada
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Application granted granted Critical
Publication of ATE255091T1 publication Critical patent/ATE255091T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)
AT01114083T 1994-09-20 1995-09-20 1-acetyl-5-bromo-4,6-dimethylindolin ATE255091T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP22516694A JP3720395B2 (ja) 1994-09-20 1994-09-20 新規ヘテロ環誘導体、その製造方法およびその医薬用途

Publications (1)

Publication Number Publication Date
ATE255091T1 true ATE255091T1 (de) 2003-12-15

Family

ID=16824983

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01114083T ATE255091T1 (de) 1994-09-20 1995-09-20 1-acetyl-5-bromo-4,6-dimethylindolin
AT95932172T ATE244220T1 (de) 1994-09-20 1995-09-20 Neue heterocyclische verbindungen, verfahren zu deren herstellung sowie medizinische verwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT95932172T ATE244220T1 (de) 1994-09-20 1995-09-20 Neue heterocyclische verbindungen, verfahren zu deren herstellung sowie medizinische verwendung

Country Status (13)

Country Link
US (4) US5990150A (de)
EP (2) EP0782986B1 (de)
JP (1) JP3720395B2 (de)
KR (1) KR100365503B1 (de)
AT (2) ATE255091T1 (de)
AU (1) AU693261B2 (de)
CA (1) CA2200472A1 (de)
DE (2) DE69532216T2 (de)
DK (2) DK1136474T3 (de)
ES (2) ES2206367T3 (de)
HK (1) HK1040513B (de)
PT (2) PT782986E (de)
WO (1) WO1996009287A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3720395B2 (ja) 1994-09-20 2005-11-24 京都薬品工業株式会社 新規ヘテロ環誘導体、その製造方法およびその医薬用途
KR100388345B1 (ko) 1995-10-05 2004-03-30 교토 야쿠힝 고교 가부시키가이샤 신규헤테로시클릭유도체및이것의의약용도
US5861496A (en) * 1996-11-07 1999-01-19 Incyte Pharmaceuticals, Inc. Human squalene epoxidase
US20060046841A1 (en) * 2004-11-12 2006-03-02 Walker Jay S Budget-based flat rate play contract parameters
US5929250A (en) * 1997-01-23 1999-07-27 Smithkline Beecham Corporation IL-8 receptor antagonists
AR008331A1 (es) * 1997-01-23 1999-12-29 Smithkline Beecham Corp Compuestos antagonistas de un receptor de il-8, uso de los mismos para la fabricacion de medicamentos, procedimiento para su obtencion, composicionesfarmaceuticas que los contienen
AR015425A1 (es) * 1997-09-05 2001-05-02 Smithkline Beecham Corp Compuestos de benzotiazol, composicion farmaceutica que los contiene, su uso en la manufactura de un medicamento, procedimiento para su preparacion,compuestos intermediarios y procedimiento para su preparacion
US6861448B2 (en) * 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
US6673827B1 (en) 1999-06-29 2004-01-06 The Uab Research Foundation Methods of treating fungal infections with inhibitors of NAD synthetase enzyme
JP2002509149A (ja) 1998-01-14 2002-03-26 ザ ユーエイビー リサーチ ファウンデイション 細菌ｎａｄシンテターゼ酵素の阻害剤の合成およびスクリーニング方法、その化合物、ならびに細菌ｎａｄシンテターゼ酵素の阻害剤を用いる細菌および微生物感染の治療方法
IL140983A0 (en) * 1998-07-23 2002-02-10 Smithkline Beecham Corp Il-8 receptor antagonists
FR2783519B1 (fr) * 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
WO2002020009A1 (fr) * 2000-09-01 2002-03-14 Sankyo Company, Limited Compositions medicales
TW200600497A (en) * 2001-02-02 2006-01-01 Sankyo Co Preparation of indoline derivative
WO2002072147A1 (fr) * 2001-03-14 2002-09-19 Sankyo Company, Limited Compositions medicinales contenant un inhibiteur de transporteur d'acide biliaire
WO2003020315A1 (fr) * 2001-08-28 2003-03-13 Sankyo Company, Limited Compositions medicinales contenant un antagoniste du recepteur d'angiotensine ii
US20050119314A1 (en) * 2002-04-05 2005-06-02 Sankyo Company, Limited Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
CN100349868C (zh) 2002-07-17 2007-11-21 京都药品工业株式会社 二氢吲哚化合物和其医药用途
US20070161698A1 (en) * 2003-05-30 2007-07-12 Microbia, Inc. Modulators of CRTH2 Activity
US7205329B2 (en) * 2003-05-30 2007-04-17 Microbia, Inc. Modulators of CRTH2 activity
JP2007527397A (ja) * 2003-07-01 2007-09-27 マイクロバイア インコーポレイテッド Ｃｏｘ−２及びｆａａｈ阻害剤
WO2005037227A2 (en) * 2003-10-16 2005-04-28 Microbia, Inc. Selective cox-2 inhibitors
CA2546601A1 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US20050234244A1 (en) * 2004-04-20 2005-10-20 Wilmin Bartolini Synthesis of COX-2 and FAAH inhibitors
US20050234030A1 (en) * 2004-04-20 2005-10-20 Wilmin Bartolini Modulators of CRTH2, COX-2 and FAAH
CA2624601C (en) 2004-10-06 2018-07-03 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
MX2007005129A (es) * 2004-10-27 2007-09-11 Daiichi Sankyo Co Ltd Compuesto de benceno que tiene 2 o mas sustituyentes.
US8022188B2 (en) * 2006-04-24 2011-09-20 Abbott Laboratories Immunosuppressant binding antibodies and methods of obtaining and using same
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
US7914999B2 (en) * 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
JP4968611B2 (ja) * 2006-12-29 2012-07-04 アボット・ラボラトリーズ 免疫抑制剤の改善された測定法
WO2008082984A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Non-denaturing lysis reagent for use with capture-in-solution immunoassay
CA2672972C (en) * 2006-12-29 2015-06-23 Abbott Laboratories Diagnostic test for the detection of a molecule or drug in whole blood
JP5134692B2 (ja) * 2007-12-19 2013-01-30 アボット・ラボラトリーズ 免疫アッセイのための免疫抑制剤薬剤抽出試薬
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1169450B (de) * 1960-08-19 1964-05-06 Hoechst Ag Verfahren zur Herstellung von Indolinderivaten und deren Salzen
US3824230A (en) * 1969-11-03 1974-07-16 Upjohn Co 1,2,4,5-tetrahydropyrrolo(3,2,1-jk)(1,4)benzodiazepin-7(6h)-ones and 1,2,4,5-tetrahydropyrrolo(1,2,3-ef)(2,5)benzodiazepin-6(7h)-ones
JPS5484572A (en) * 1977-12-14 1979-07-05 Mitsui Petrochem Ind Ltd Preparation of 1-acyl-5-bromoindoline
US4615966A (en) * 1985-07-03 1986-10-07 Polaroid Corporation Color transfer photographic processes and products with indole phthalein filter dyes
JPH02117651A (ja) * 1988-01-20 1990-05-02 Yamanouchi Pharmaceut Co Ltd ジウレア誘導体及びその製造法
IE892088L (en) * 1988-07-12 1990-01-12 William Henry Deryk Morris Quinoline derivatives, their production and use
JPH0753714B2 (ja) * 1988-07-12 1995-06-07 武田薬品工業株式会社 Ａｃａｔ阻害剤、キノリン誘導体及びその製造法
EP0375133A1 (de) * 1988-11-14 1990-06-27 The Upjohn Company Alpha-amino-indol-3-essigsäure, verwendbar als antidiabetische, antifettleibige und antiarteriosklerotische Agenten
CA2030557A1 (en) * 1989-03-31 1990-10-01 Hiroshi Matsui Imidazole derivatives, methods for their production and pharmaceutical use thereof
JPH03181465A (ja) * 1989-12-11 1991-08-07 Takeda Chem Ind Ltd キノリン誘導体
JPH0466568A (ja) * 1990-06-29 1992-03-02 Takeda Chem Ind Ltd 中枢性抗酸化剤化合物
US5256782A (en) * 1990-08-17 1993-10-26 Takeda Chemical Industries, Ltd. Thienopyridine derivatives which are intermediates
US5143919A (en) * 1990-08-17 1992-09-01 Takeda Chemical Industries, Ltd. Thienopyridine derivatives and their pharmaceutical use
FR2673625B1 (fr) * 1991-03-08 1993-05-07 Adir Nouveaux derives d'acylaminophenol, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5254919A (en) 1991-03-22 1993-10-19 Eastman Kodak Company Encoder system using linear array sensor for high resolution
FR2674522B1 (fr) * 1991-03-26 1993-07-16 Lipha Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant.
AU1886892A (en) * 1991-04-12 1992-11-17 Schering Corporation Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase
IL101785A0 (en) * 1991-05-10 1992-12-30 Fujisawa Pharmaceutical Co Urea derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
WO1994014801A1 (en) * 1992-12-29 1994-07-07 Smithkline Beecham Plc Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists
JP3720395B2 (ja) 1994-09-20 2005-11-24 京都薬品工業株式会社 新規ヘテロ環誘導体、その製造方法およびその医薬用途
KR100388345B1 (ko) * 1995-10-05 2004-03-30 교토 야쿠힝 고교 가부시키가이샤 신규헤테로시클릭유도체및이것의의약용도

Also Published As

Publication number Publication date
EP1136474B1 (de) 2003-11-26
AU693261B2 (en) 1998-06-25
HK1040513A1 (en) 2002-06-14
PT1136474E (pt) 2004-04-30
DE69532216D1 (de) 2004-01-08
ES2200003T3 (es) 2004-03-01
US6414012B1 (en) 2002-07-02
CA2200472A1 (en) 1996-03-28
WO1996009287A1 (fr) 1996-03-28
US6489475B2 (en) 2002-12-03
HK1040513B (zh) 2004-06-18
PT782986E (pt) 2003-11-28
US6127403A (en) 2000-10-03
EP0782986B1 (de) 2003-07-02
EP1136474A1 (de) 2001-09-26
DE69531213D1 (de) 2003-08-07
KR970706252A (ko) 1997-11-03
KR100365503B1 (ko) 2003-06-12
DK0782986T3 (da) 2003-10-06
DK1136474T3 (da) 2004-02-23
DE69531213T2 (de) 2004-04-15
ES2206367T3 (es) 2004-05-16
US20010014740A1 (en) 2001-08-16
US5990150A (en) 1999-11-23
AU3532495A (en) 1996-04-09
JP3720395B2 (ja) 2005-11-24
JPH0892210A (ja) 1996-04-09
ATE244220T1 (de) 2003-07-15
DE69532216T2 (de) 2004-09-16
EP0782986A4 (de) 2000-04-05
EP0782986A1 (de) 1997-07-09

Similar Documents

Publication Publication Date Title
ATE255091T1 (de) 1-acetyl-5-bromo-4,6-dimethylindolin
HK1048989A1 (en) Heterocyclic derivatives and pharmaceutical use thereof.
NO302470B1 (no) Substituerte heterocykliske karboksylsyreamider, og deres anvendelse ved fremstilling av legemiddel
AU692090B2 (en) Novel 4,6-diarylpyrimidine derivatives and salts thereof
ES538847A0 (es) Un derivado de fenilserina
ATE114154T1 (de) Thienotriazolodiazepine und ihre pharmazeutische verwendung.
DE69713648D1 (de) Benzopyranderivate und ihre Verwendung zur Behandlung von Herzkrankheiten
FI896228A0 (fi) Analogiamenetelmä valmistaa lääkeaineina käyttökelpoisia uusia karboksimidiamidijohdannaisia tai niiden farmaseuttisesti sopivia happoadditiosuoloja
AU2013888A (en) Uricosuric composition

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1136474

Country of ref document: EP

REN Ceased due to non-payment of the annual fee